PHARM Stock Overview
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally.
Pharming Group Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||€0.77|
|52 Week High||€1.03|
|52 Week Low||€0.66|
|1 Month Change||-4.98%|
|3 Month Change||-0.39%|
|1 Year Change||-24.31%|
|3 Year Change||-0.72%|
|5 Year Change||143.53%|
|Change since IPO||-99.18%|
Recent News & Updates
|PHARM||NL Biotechs||NL Market|
Return vs Industry: PHARM underperformed the Dutch Biotechs industry which returned -16.6% over the past year.
Return vs Market: PHARM underperformed the Dutch Market which returned -16.9% over the past year.
|PHARM Average Weekly Movement||5.4%|
|Biotechs Industry Average Movement||8.2%|
|Market Average Movement||5.6%|
|10% most volatile stocks in NL Market||8.5%|
|10% least volatile stocks in NL Market||3.7%|
Stable Share Price: PHARM is not significantly more volatile than the rest of Dutch stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: PHARM's weekly volatility (5%) has been stable over the past year.
About the Company
|n/a||277||Simon de Vries||https://www.pharming.com|
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company’s lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases.
Pharming Group Fundamentals Summary
|PHARM fundamental statistics|
Is PHARM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PHARM income statement (TTM)|
|Cost of Revenue||US$21.18m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 04, 2022
|Earnings per share (EPS)||0.017|
|Net Profit Margin||5.41%|
How did PHARM perform over the long term?See historical performance and comparison
Is Pharming Group undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: PHARM (€0.77) is trading below our estimate of fair value (€2)
Significantly Below Fair Value: PHARM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: PHARM is poor value based on its Price-To-Earnings Ratio (49.4x) compared to the European Biotechs industry average (36.4x).
PE vs Market: PHARM is poor value based on its Price-To-Earnings Ratio (49.4x) compared to the Dutch market (15.2x).
Price to Earnings Growth Ratio
PEG Ratio: PHARM is poor value based on its PEG Ratio (1.4x)
Price to Book Ratio
PB vs Industry: PHARM's Price-To-Book Ratio (2.8x) is in line with the XE Biotechs industry average.
How is Pharming Group forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Future Growth Score4/6
Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHARM's forecast earnings growth (34.7% per year) is above the savings rate (0.09%).
Earnings vs Market: PHARM's earnings (34.7% per year) are forecast to grow faster than the Dutch market (2.3% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PHARM's revenue (11.6% per year) is forecast to grow faster than the Dutch market (7% per year).
High Growth Revenue: PHARM's revenue (11.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PHARM's Return on Equity is forecast to be high in 3 years time
How has Pharming Group performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: PHARM has a large one-off loss of $10.4M impacting its March 31 2022 financial results.
Growing Profit Margin: PHARM's current net profit margins (5.4%) are lower than last year (18.4%).
Past Earnings Growth Analysis
Earnings Trend: PHARM has become profitable over the past 5 years, growing earnings by 50.8% per year.
Accelerating Growth: PHARM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: PHARM had negative earnings growth (-70.6%) over the past year, making it difficult to compare to the Biotechs industry average (-6.2%).
Return on Equity
High ROE: PHARM's Return on Equity (5.6%) is considered low.
How is Pharming Group's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: PHARM's short term assets ($250.9M) exceed its short term liabilities ($45.2M).
Long Term Liabilities: PHARM's short term assets ($250.9M) exceed its long term liabilities ($153.6M).
Debt to Equity History and Analysis
Debt Level: PHARM has more cash than its total debt.
Reducing Debt: PHARM's debt to equity ratio has reduced from 226.9% to 70.8% over the past 5 years.
Debt Coverage: PHARM's debt is well covered by operating cash flow (22.8%).
Interest Coverage: PHARM's interest payments on its debt are well covered by EBIT (3.5x coverage).
What is Pharming Group current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate PHARM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate PHARM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if PHARM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if PHARM's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as PHARM has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Simon de Vries (62 yo)
Dr. Sijmen De Vries, also known as Simon, M.D., M.B.A., has been the Chief Executive Officer of Pharming Group NV since November 3, 2008 and also serves as its Executive Director. He serves as President at...
CEO Compensation Analysis
Compensation vs Market: Simon's total compensation ($USD2.46M) is above average for companies of similar size in the Dutch market ($USD1.11M).
Compensation vs Earnings: Simon's compensation has been consistent with company performance over the past year.
Experienced Management: PHARM's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Experienced Board: PHARM's board of directors are not considered experienced ( 1.4 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: PHARM insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Pharming Group N.V.'s employee growth, exchange listings and data sources
- Name: Pharming Group N.V.
- Ticker: PHARM
- Exchange: ENXTAM
- Founded: NaN
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €502.914m
- Shares outstanding: 651.44m
- Website: https://www.pharming.com
Number of Employees
- Pharming Group N.V.
- Darwinweg 24
- 2333 CR
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.